A Science Translational Medicine study reports that folate receptor alpha (FOLR1) supports immune evasion in colorectal cancer by disrupting STAT1 signaling, dampening MHC-1 activity, and limiting CD8+ T-cell engagement. In mouse models, targeting FOLR1 with mirvetuximab soravtansine restored anti-tumor immune activity and resensitized tumors to anti–PD-1 blockade. The work links FOLR1 expression in human colorectal tumors to poorer outcomes and identifies a mechanistic pathway through which the receptor helps maintain treatment resistance. For translational teams, the findings expand the set of resistance mechanisms beyond antigen presentation defects alone and suggest combination sequencing strategies where FOLR1-directed therapy may be used to re-open checkpoint responsiveness.